CND Life Sciences Raises Growth Capital for Neurodiagnostics

CND Life Sciences has successfully closed a significant growth financing round, with S-Curve Partners taking the lead. This infusion of capital is earmarked to accelerate the market penetration of its innovative Syn-One Test and bolster its comprehensive neurodiagnostics platform. The investment also saw participation from existing stakeholders within CND Life Sciences, underscoring their continued belief in the company's trajectory. While specific financial figures remain undisclosed, the strategic importance of this funding is clear.

The Syn-One Test represents a pivotal advancement in the early detection of neurodegenerative conditions. This laboratory-developed test utilizes skin biopsies to identify abnormal phosphorylated alpha-synuclein and other pathological indicators. Its clinical utility is crucial for physicians evaluating patients presenting with symptoms suggestive of Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and REM sleep behavior disorder, collectively known as synucleinopathies. The market for accurate and early diagnostic tools in neurology is substantial, with the global neurodegenerative disease market projected to reach hundreds of billions of dollars in the coming years, driven by an aging population and increased disease awareness.

Since its introduction in 2020, the Syn-One Test has gained considerable traction within the medical community. Over 4,000 neurologists and other healthcare professionals across the United States have integrated the test into their diagnostic workflows, contributing to the evaluation of more than 60,000 patient cases. This widespread adoption highlights the unmet need for reliable diagnostic solutions in this complex field. The company's commitment to expanding its commercial reach is a key focus for the newly acquired funds.

CND Life Sciences intends to strategically deploy the growth financing to several critical areas. Beyond expanding the commercial footprint of the Syn-One Test, the company plans to invest heavily in ongoing product development initiatives, aiming to enhance the test's capabilities and explore new diagnostic markers. Furthermore, the capital will facilitate the formation of strategic partnerships, crucial for integrating the Syn-One platform into a more expansive, multimodal biomarker ecosystem designed for the diagnosis and characterization of neurodegenerative diseases. This approach aligns with the growing trend in neuroscience towards integrated diagnostic strategies.

The company's engagement extends to the biopharmaceutical sector, where CND Life Sciences collaborates with drug developers on clinical trials. Their research efforts are also directed towards achieving even earlier disease detection and refining the quantification of synuclein, a key protein implicated in several neurological disorders. This dual focus on clinical diagnostics and research support positions CND Life Sciences as a valuable partner in the fight against neurodegenerative diseases.

Daniel Livschutz, Founding Partner at S-Curve Partners, commented on the investment, stating, “We believe CND has built one of the most differentiated platforms in neurodiagnostics, and this financing is intended to accelerate its evolution from a category-defining product to a broader platform supporting earlier diagnosis, disease differentiation, and more personalized care.” This sentiment is echoed by Rick Morello, CEO of CND Life Sciences, who noted, “S-Curve’s confidence in CND’s mission reflects the progress our team has made in expanding clinical adoption and advancing the science behind our scalable neurodiagnostics platform.” Dr. Todd Levine, Chief Medical Officer and Co-Founder of CND Life Sciences, added, “As a neurologist, I am encouraged to see the neuroscience field move toward multimodal biomarkers and earlier intervention. This financing gives us the flexibility to invest in innovation, expand access to the Syn-One platform, and strengthen our pharmaceutical and research relationships.”